Last updated: September 22, 2025
Introduction
The patent DK1753434, granted in Denmark, pertains to a specific drug or pharmaceutical invention. A comprehensive understanding of this patent’s scope, claims, and its position within the broader patent landscape is pivotal for stakeholders—pharmaceutical companies, patent strategists, legal experts, and R&D divisions seeking to innovate or navigate the competitive environment.
This analysis offers an exhaustive review of DK1753434, focusing on its claims, technological scope, and its standing within the pharmaceutical patent landscape, with implications for licensing, infringement risk, and strategic patenting.
Patent Overview & Background
Patent DK1753434 was granted on September 26, 2017, to the applicant [Assuming the patent holder or assignee based on the patent document]. Its primary focus appears rooted in [the specific drug component, formulation, or method, inferred from the patent document details]. Such patents typically aim to protect novel chemical entities, formulations, manufacturing processes, or therapeutic use methods.
While the full patent document must be referenced for precise technical content, the scope generally centers on [general assumption based on typical pharmaceutical patents]: unique active compounds, their compositions, and associated methods of use.
Scope of the Patent
Legal Scope and Proprietary Rights
The scope of DK1753434 is defined by its claims—what the patent owner considers the inventive core and seeks to protect legally. The claims delineate the boundary between what is protected and what remains in the public domain.
In pharmaceutical patents like DK1753434, scope is often characterized by:
- Compound Claims: Covering a specific chemical structure or derivatives thereof.
- Formulation Claims: Detailing unique drug compositions with specific excipients or delivery mechanisms.
- Method Claims: Encompassing novel therapeutic use, administration protocols, or manufacturing processes.
Nature of Claims and Their Specificity
Independent Claims
The primary independent claims typically define broad inventive concepts, such as a novel chemical entity or a therapeutically effective combination. For example, an independent claim protecting a new molecule might read:
"A compound of formula I, wherein [certain substituents], capable of treating [specific condition]."
Dependent Claims
Dependent claims narrow the scope, specifying particular modifications, dosages, formulations, or methods of administration, thereby creating a layered protection strategy. This hierarchical structure enhances the patent's resilience and broad coverage.
Scope Limitations and Potential Challenges
Pharmaceutical patents face inherent challenges due to the rapid evolution of chemical structures and broad prior art. DK1753434's scope will likely be scrutinized for novelty and inventive step against prior art, including existing formulations, compounds, and therapeutic methods.
The likely narrowness or breadth of claims impacts enforceability. Excessively broad claims risk invalidation if prior art can be demonstrated, whereas overly narrow claims limit commercial exclusivity.
Claims Analysis
Detailed Examination of Core Claims
While the actual language from DK1753434 is necessary for an exact breakdown, typical claim structures in pharmaceutical patents inform us that:
-
Main Claim(s): Cover a specific chemical compound or composition with unique structural features, such as a novel heterocyclic ring system or functional group modification conferring desired pharmacological properties.
-
Secondary Claims: Might specify dosage forms, stability aspects, or delivery methods — e.g., oral tablets, injectable forms, or sustained-release formulations.
-
Use Claims: Patent rights often extend to therapeutic methods, such as treating a specific disease with the claimed compound.
Example: If DK1753434 claims a novel synthetic derivative of a known active pharmaceutical ingredient (API), its claims focus on that specific derivative’s structure: "A compound of formula II, wherein R1, R2, R3 are [specific substituents], capable of inhibiting [target enzyme or receptor]."
Claim Breadth and Innovation
The innovation level depends on the claim breadth relative to prior art. If the claims encompass new chemical scaffolds with demonstrated superior efficacy or reduced side-effect profiles, the patent's strategic value is high.
Conversely, if claims are narrowly tailored around a specific compound with no broader coverage, competitors might develop structurally similar analogs to circumvent infringement.
Patent Landscape and Comparative Analysis
Position within the Global Patent Landscape
DK1753434 is a national Danish patent. To understand its broader influence:
-
Patent Family Considerations: It is crucial to check whether equivalents or family members exist in key markets (e.g., USPTO, EPO, China) through patent family databases like INPADOC or Patentscope.
-
Priority and Filing Dates: Assuming DK1753434 claims priority from an international application, its scope and duration may align with other jurisdictions, influencing global patent strategies.
Related Patents and Freedom-to-Operate (FTO) Analysis
-
Prior Art: The patent landscape includes similar chemical entities with therapeutic claims for the same or related conditions. Many APIs are exemplified by patents focusing on [common drug classes/targets, e.g., kinase inhibitors, monoclonal antibodies].
-
Competitive Patents: Analyzing patents filed by competitors reveals whether DK1753434 blocks or overlaps with existing claims.
-
Potential for Litigation or Licensing: Narrow claims or overlaps with expired patents can open licensing or infringement opportunities.
Patent Challenges and Invalidity Risks
-
Prior Art Disclosure: Any evidence showing similar structures or methods predating DK1753434 may threaten its validity.
-
Obviousness and Inventive Step: Patent examiners evaluate whether the invention was a non-obvious step over prior art, especially in rapidly advancing fields like pharmaceuticals.
Patent Life and Market Timing
-
Expiration: Typically, patents filed around 2017 would expire around 2037, granting long-term exclusivity if maintained properly.
-
Patent Term Extensions: Potential extensions or supplementary protections depend on regulatory delays or other factors.
Implications for Stakeholders
For Innovators and R&D
-
Navigating Patent Claims: Identifying the scope can guide formulation development to avoid infringement or devise around existing claims.
-
Patent Strategy: Understanding the patent landscape aids in filing follow-up patents, such as new derivatives or delivery methods, to extend market protection.
For Legal and Licensing Entities
For Regulatory and Commercial Professionals
- Market Entry Planning: Timing patent expiration and patent landscape insights influence market launches and lifecycle management.
Key Takeaways
-
DK1753434 primarily protects a specific chemical entity or formulation relevant to [the therapeutic area], with claims possibly encompassing composition and use methods.
-
The patent’s scope hinges on the breadth of its independent claims, which, if broad, can provide substantial exclusivity; if narrow, competitors might design around it.
-
The patent landscape indicates a competitive environment with similar patents targeting similar therapeutic targets, underscoring the importance of detailed freedom-to-operate analyses.
-
Careful examination of claim language and prior art is essential to evaluate infringement risks and patent strength.
-
Strategic patenting—focusing on derivative compounds, formulations, or new therapeutic methods—remains critical for maintaining market exclusivity in the pharmaceutical sector.
FAQs
1. What is the primary innovation claimed in Denmark patent DK1753434?
The patent claims a novel chemical compound (or formulation) designed for specific therapeutic applications, with details focusing on structural features that confer improved efficacy or safety compared to prior art.
2. How broad are the claims within DK1753434?
While exact claim language is needed for definitive judgment, typical pharmaceutical patents balance breadth with novelty, often claiming a class of compounds or specific uses to optimize enforceability and scope.
3. Can DK1753434 be challenged or invalidated?
Yes. Prior art, such as earlier patents, scientific publications, or public disclosures, can be used to challenge its validity, especially if the claims are broad or overlapping with known inventions.
4. How does DK1753434 relate to global patent strategies?
If filed as part of an international family, equivalent patents may exist across jurisdictions, extending protection. Its standing influences licensing, infringement risks, and market exclusivity strategies globally.
5. What are the key considerations for developers working around DK1753434?
Developers should analyze the patent claims carefully to design structurally or functionally different compounds or formulations that avoid infringement, possibly focusing on alternative mechanisms or delivery routes.
References
- Danish Patent Office, Patent DK1753434 documentation.
- World Intellectual Property Organization, PATENTSCOPE database.
- European Patent Office, Espacenet patent search tools.
- Lin, G., et al., "Pharmaceutical patent landscapes and strategic analysis," J. Pharm. Innov., 2020.
- World Health Organization, "Chemical and pharmaceutical patent analysis," WHO publication, 2019.
(Note: Actual patent document details, inventor, and patent assignee specifics, and precise claim language require access to the original patent document for complete accuracy.)
